Table 5.
Patients | Number of LVs | Sensitivity | Specificity |
---|---|---|---|
Healthy donors versus prostate cancer patients | 07 | 92% | 90% |
GS 9 versus GS 8 | 03 | 65% | 85% |
GS 9 versus GS 7 | 10 | 85% | 95% |
GS 8 versus GS 7 | 13 | 80% | 75% |
GS, Gleason score; PLS-DA, partial least squares discriminant analysis.